Actively Recruiting
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
Led by Washington State University · Updated on 2026-03-10
104
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
W
Washington State University
Lead Sponsor
T
Terra Mater Botanicals Pty Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the effects of hemp-derived minor cannabinoids on symptoms experienced during menopause and perimenopause. This randomized, double-blind, placebo-controlled trial aims to understand how these cannabinoids may influence psychological and physical symptoms in women aged 40 to 60. The study spans three months and includes careful monitoring of emotional, cognitive, and physical health factors associated with menopause. Participants will be randomly assigned to receive either an active hemp-derived cannabinoid product or a placebo, taken three times daily after meals. The study includes a baseline period of four weeks with twice-daily symptom and sleep surveys, weekly cognitive testing via smartphone, and monthly Zoom sessions for detailed cognitive assessments and symptom surveys. Following baseline, two phases of four weeks each will continue with the assigned product, maintaining the same schedule of surveys, cognitive tests, and Zoom assessments. During the study, participants will complete frequent ecological momentary assessments (EMA) twice daily to report symptoms and side effects, along with weekly cognitive tests on memory, attention, and reaction time. Monthly Zoom sessions will include comprehensive cognitive tests and surveys assessing depression, anxiety, stress, sleep, and memory. Researchers will closely monitor mood, physical symptoms, side effects, and cognitive function throughout the three-month study to evaluate the impact of the cannabinoids on menopause symptoms.
CONDITIONS
Brief Title
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Designated female at birth
- Aged between 40 and 60 years
- Able to give informed consent without intellectual disability
- Stable medication regimen with no changes in the past 3 months
- Abstinent from regular cannabis use (less than once per month) for the past year and willing to abstain during the study
- Abstinent from supplements with no changes in the past 3 months
- Own a smartphone
- Access to Zoom with a secure, stable internet connection
- Experiencing menopause or perimenopause
You will not qualify if you...
- Currently taking antidepressant, anti-anxiety, or antipsychotic medications
- Severe depression, neurovegetative symptoms, or current suicidality
- Psychosis or family history of psychosis
- Pregnant or breastfeeding
- Undergoing chemotherapy
- Low blood pressure (hypotension)
- Required drug testing for work or other reasons
- Illicit drug use in the past 3 months (excluding cannabis)
- Heavy alcohol use (4 or more drinks more than 4 times per week)
- Planned international or air travel longer than one week in the next 3 months
- Allergy to coconut
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 online screening survey
Duration - 4 weeks
Participants complete baseline assessments including cognitive tests during an initial Zoom session, followed by 4 weeks of ecological momentary assessment (EMA) surveys twice daily and weekly EMA cognitive tests. They also complete monthly online surveys and cognitive tests via Zoom.
1 initial Zoom visit, twice daily EMA surveys for 4 weeks, weekly EMA cognitive tests, 1 monthly Zoom visit
Duration - 4 weeks
Participants take the active or placebo product three times daily with a dose escalation during the first week. They complete twice daily EMA surveys after morning and evening doses, weekly EMA cognitive tests, and monthly cognitive tests and surveys via Zoom.
Twice daily EMA surveys, weekly EMA cognitive tests, 1 monthly Zoom visit
Duration - 4 weeks
Participants continue taking the active or placebo product three times daily. They complete twice daily EMA surveys after morning and evening doses, weekly EMA cognitive tests, and monthly cognitive tests and surveys via Zoom. The study ends after this phase.
Twice daily EMA surveys, weekly EMA cognitive tests, 1 monthly Zoom visit
Trial Site Locations
Total: 1 location
1
Washington State University, Dept of Psychology
Pullman, Washington, United States, 99164
Actively Recruiting
Research Team
C
Carrie Cuttler, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here